Press Releases Subscribe to our News
25. Mai 2022
02. Mai 2022
Non-Regulatory
Biosergen is preparing a Phase II study of BSG005 against Mucormycosis, the Black Fungus.
Release
19. April 2022
Non-Regulatory
The first subjects dosed successfully with no adverse events in the phase I trial of BSG005
Release
24. August 2021
Non-Regulatory
Biosergen’s application to start human clinical trials with BSG005 is approved
Release
19. August 2021
23. Juni 2021
Non-Regulatory
BIOSERGEN HAS BEEN APPROVED FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM.
Biosergen listing approval
31. Mai 2021
Non-Regulatory
The outbreak of mucormycosis (the so-called “Black Fungus”) in India is a prime example of the great need for a safer antifungal drug with true fungicidal activity
Release
19. Mai 2021
Non-Regulatory
BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM
BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM (PDF)Non-Regulatory
